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Summary
STUDY PRINCIPLE: To estimate the prevalence of un-
known impaired glucose metabolism, also referred to as
prediabetes (PreD), and unknown type 2 diabetes mellitus
(T2DM) among subjectively healthy Swiss senior citizens.
The fasting plasma glucose (FPG) and glycated haemo-
globin A1c (HbA1c) levels were used for screening. A total
of 1 362 subjects were included (613 men and 749 women;
age range 60–99 years). Subjects with known T2DM were
excluded.
METHODS: The FPG was processed immediately for ana-
lysis under standardised preanalytical conditions in a cross-
sectional cohort study; plasma glucose levels were meas-
ured by means of the hexokinase procedure, and HbA1c
was measured chromatographically and classified using the
current American Diabetes Association (ADA) criteria.
RESULTS: The crude prevalence of individuals unaware
of having prediabetic FPG or HbA1c levels, was 64.5% (n
= 878). Analogously, unknown T2DM was found in 8.4%
(n = 114) On the basis of HbA1c criteria alone, signific-
antly more subjects with unknown fasting glucose impair-
ment and laboratory T2DM could be identified than with
the FPG. The prevalence of PreD as well as of T2DM in-
creased with age. The mean HOMA indices (homeostasis
model assessment) for the different age groups, between
2.12 and 2.59, are consistent with clinically hidden disease
and are in agreement with the largely orderly Body Mass
Indices found in the normal range.
CONCLUSIONS: Laboratory evidence of impaired gluc-
ose metabolism and, to a lesser extent, unknown T2DM,
has a high prevalence among subjectively healthy older
Swiss individuals. Laboratory identification of people with
unknown out-of-range glucose values and overt diabetic
hyperglycaemia might improve the prognosis by delaying
the emergence of overt disease.
Key words: fasting glucose; type 2 diabetes mellitus;
HbA1c; HOMA index; geriatrics; healthy aging
Introduction
Chronic noncommunicable diseases are reaching epidemic
proportions, and they affect people of all ages. In Switzer-
land, 4.7 to 7% of the population suffers from type 2 dia-
betes mellitus (T2DM). The occurrence of T2DM is
gender-dependent: it is lower in women than in men (3.9%
vs 5.5%) [1]. The prevalence increases to 11.0% in subjects
aged 65–74 years and to 12.5% in individuals ≥75 years.
The prevalence of T2DM, defined as glycated haemoglobin
A1c (HbA1c) ≥6.5% or fasting plasma glucose (FPG) ≥7.0
mmol/l, is rising in our country, with an increase of 1.4%
over the last 15 years; the increase in the population aged
≥75 years is even higher (3.2%). The SENIORLAB study
results reported here are the product of clinical chemical
laboratory screening.
Despite the wealth of epidemiological data on manifest dia-
betic disease, the prevalence data for impaired glucose reg-
ulation are limited. Each of the following categories, in-
cidentally termed prediabetes (PreD), represents a status of
impaired glucose metabolism associated with an increased
risk to develop T2DM:
i. Impaired fasting glucose (IFG) – fasting plasma gluc-
ose (FPG) ≥5.6 mmol/l to 6.9 mmol/l (≥100 mg/dl to
125 mg/dl).
ii. Impaired glucose tolerance (IGT) – plasma glucose
≥7.8 mmol/l to 11.9 mmol/l (≥140 mg/dl to 199 mg/dl)
measured two hours after a glucose load of 1.75 g/kg
(maximum dose of 75 g) in an oral glucose tolerance
test (OGTT).
iii. Haemoglobin A1C values between 5.7 and 6.4% (39 to
46 mmol/mol) are also being considered by some to in-
dicate risk for T2DM and have been viewed as PreD in
adults.
The approach for diagnosis/prevalence of unequivocal
PreD has been the subject of recent updates [2–6].
In 2010, about one-third of adults in the USA (~79 million
people) had PreD, a metabolic state of care seekers with
FPG or HbA1c levels near the upper cut-off of the reference
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range, but not high enough to indicate T2DM [2, 3]. Recent
studies have shown that only 11.9% of older people (≥65
years) diagnosed with PreD were aware of this problem of
glucose regulation [7]; to appreciate the extent of inherent
insulin resistance, a homeostasis model assessment that in-
cludes the FPG and insulin levels is now used for its estim-
ation (HOMA-IR).
Our study defends laboratory screening for impaired gluc-
ose regulation as part of a strategy to avoid impending dia-
betes, i.e. to reduce the risk of progression to overt dis-
ease [8, 9]. According to a recent study, individuals who
are diagnosed with PreD from the combination of FPG and
HbA1c results had a significantly increased risk of T2DM
[10]. The HbA1c reflects the long-term glycaemic exposure
and is now a reliable test, except with haemoglobin variants
unlikely to be present in the SENIORLAB cohort analysed
here [11–13]); in contrast to FPG, quantitation of the HbA1c
does not require fasting, with a 2-hour wait in the case of
an OGTT, and the wider reference interval of HbA1c values
better facilitates assessment of the risk forT2DM than the
narrow reference interval of FPG. Such factors as obesity,
arterial hypertension and lack of exercise merit special at-
tention. These advantages should lead to increased identi-
fication and more timely treatment of people with impaired
glucose regulation in the category of PreD or calculated
T2DM.
The aim of the present study was to determine the preval-
ence of impaired glucose regulation, PreD and T2DM by
laboratory screening of the FPG and HbA1c in subjectively
healthy Swiss senior citizens (SENIORLAB).
Methods
Study population
This analysis was a cross-sectional cohort study. Consec-
utive, subjectively healthy senior volunteers of Western
Figure 1
Study flow diagram.
In addition to the exclusions for known diabetes mellitus, we had to
exclude subjects in whom the relevant laboratory tests were not
available. * Four participants fulfilled both exclusion criteria.
European descent and ≥60 years of age were recruited
between February 2009 and December 2011 as part of the
SENIORLAB cohort (ISRCTN registry no. 53778569), a
prospective observational study on the Swiss plateau aimed
at creating appropriate reference intervals (RIs) of several
analytes in senior citizens (http://www.seniorlabor.ch).
Subjectively healthy senior Caucasian volunteers, aged 60
years and older, were recruited. Participants with thyroid
disease, known diabetes mellitus, active neoplasia, hospit-
alisation within the last 30 days, treatment with more than
five drugs were excluded from participation. The study
participants were contacted through newspaper advertise-
ments, clubs and associations where there was a high prob-
ability that the membership would include healthy senior
citizens (e.g., mountaineering clubs, sports clubs) and
through the personal contacts of those involved in organ-
ising the study. A personal history of the subjects was col-
lected, anthropometric measurements (body weight, height,
and Body Mass Index [BMI]) were performed, and fasting
venous blood was drawn into S-Monovette tubes (Sarstedt,
Sevelen, Switzerland). The food intake by participants, ac-
cording to the regional Swiss standard habit, included an
approximate energy consumption per person per day in
Switzerland of 2 661 kcal (11,135 kJ), consisting of 14%
proteins, 51% carbohydrates and 35% fat [14]. None of the
participants was alcohol dependent. The exclusion criteria
on first sight included candidates knowingly suffering from
overt T2DM and missing FPG or HbA1c values (fig. 1).
Laboratory testing
The FPG level was measured using the enzymatic hex-
okinase procedure on the Roche Integra 800 (Rotkreuz,
Switzerland). HbA1c was measured by IFCC- (Internation-
al Federation of Clinical Chemistry) approved high per-
formance liquid chromatography (HPLC D-10™, Biorad,
Reinach, CH), which is an NGSP (National Glycohemo-
globin Standardization Program [www.ngsp.org]) testing
system with a coefficient of variation (CV) of <3% (CV
with units in terms of mmol/mol); it provides results con-
sistent with IFCC-assigned external quality control
samples.
Serum insulin was measured using an electrochemilumin-
escence immunoassay (ECLIA; Cobas 6000, Roche Dia-
gnostics, Baar, Switzerland). Insulin resistance (IR) was es-
timated by the Homeostasis Model Assessment (HOMA),
which is derived from a mathematical assessment of the
balance between the hepatic glucose output and insulin se-
cretion from the fasting levels of glucose (HOMA index =
serum insulin [µU/ml] x serum glucose [mmol/l] divided
by 22.5); the model requires a single measurement of in-
sulin and glucose in the basal state. The HOMA index
values and cut-offs were evaluated as ≤2.0 = no insulin
resistance, >2.0–<2.5 = indication for insulin resistance,
≥2.5–≤5.0 = insulin resistance likely; values >5.0 are
mostly seen in patients with T2DM. The accuracy and pre-
cision of our assays were within the requirements set by
the Swiss commission for quality assurance in the medical
laboratory (QUALAB).
The current ADA (American Diabetes Association) RIs
for the diagnosis of PreD (HbA1c 5.7–6.4%, FPG 5.6–6.9
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mmol/l) and T2DM (HbA1c ≥6.5%, FPG ≥7.0 mmol/l)
were applied [15].
Ethics
This study was conducted in accordance with the ethical
guidelines of the Declaration of Helsinki, and informed
consent was obtained from all participants. Ethical approv-
al for the present study was obtained from the local ethics
committee (Kantonale Ethikkommission Bern KEK [Ethic
Board Canton of Berne, Study Nr 166/08]), Bern, Switzer-
land. Participants provided written informed consent, the
standard form being kept on file for each, and KEK ap-
proved of the consent procedure used in this study.
Statistical analysis
We used descriptive statistical methods for characterisation
of the study participants. For proportions, 95% confidence
intervals (CIs) were calculated. We investigated agreement
between fasting plasma glucose and HbA1c in diagnosing
PreD and T2DM by means of Cohen’s weighted kappa stat-
istic for evaluation of interrater agreement. A kappa <0.2
indicates poor, 0.21–0.4 fair, 0.41–0.6 moderate, 0.61–0.8
good, and 0.81–1.0 very good agreement. Proportions were
compared by means of chi-squared test. Continuous results
among three or more groups were compared by the Kruskal
Wallis test followed by post-hoc analysis by the method of
Conover. A p-value <0.05 was considered statistically sig-
nificant. For statistical computation, MedCalc for Windows
software, Version 12.5 (Ostend, Belgium) was employed.
Results
Of all participants (n = 1 467), 105 were excluded, for the
following reasons: 74 declared manifest T2DM, and 35 had
missing HbA1c values (fig. 1). The remaining 1 362 sub-
jects (n = 100%) were included in the study. The demo-
Table 1: Demographics and number of participants in each age group for the homeostasis model assessment [13].
Characteristic Data
Participants, n (%) 1362 (100)
Age (years)
– Mean
– Range
72.1
60–99
Gender
– Men, n (%)
– Women, n (%)
604 (45.0)
743 (55.0)
BMI (g/m2)
– Men, median (IQR)
– Women, median (IQR)
25.5 (23.7–28.1)
24.5 (22.1–26.9)
HOMA index
– Age group 60–64 years, mean
– Age group 65–69 years, mean
– Age group 70–74 years, mean
– Age group 75–79 years, mean
– Age group 80–84 years, mean
– Age group ≥85 years, mean
2.15
2.12
2.30
2.28
2.59
2.27
Age group
60–64 years, n
– Men, n (%)
– Women, n (%)
65–69 years, n
– Men, n (%)
– Women, n (%)
70–74 years, n
– Men, n (%)
– Women, n (%)
75–79 years, n
– Men, n (%)
– Women, n (%)
80–84 years, n
– Men, n (%)
– Women, n (%)
≥85 years, n
– Men, n (%)
– Women, n (%)
255
124 (48.6)
131 (51.4)
321
145 (45.2)
176 (54.8)
298
136 (45.6)
162(54.4)
224
97 (43.3)
127 (56.7)
169
77 (45.6)
92 (54.4)
95
34 (35.8)
61 (64.2)
BMI = body mass index: HOMA = homeostasis model assessment; IQR = interquartile range
Table 2: Crude prevalence of unknown PreD and T2DM as assessed by measurement of FPG and HbA1c.
Fasting plasma glucose (female/male)
Neg PreD T2DM Total
Neg 370 (204/166) 78 (28/50) 2 (1/1) 450
PreD 549 (364/185) 251 (109/142) 6 (1/5) 806
T2DM 23 (12/11) 51 (19/32) 32 (11/21) 106
HbA1c
(female/male)
Total 942 380 40 1362
FPG = fasting plasma glucose; HbA1c = glycated haemoglobin; PreD = prediabetes; T2DM = type 2 diabetes mellitus
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graphics and number of participants per age group are
shown in table 1. The mean BMI of the participants had
values in the upper reference range for both sexes accord-
ing to the World Health Organization (WHO) definition,
and there was no significant difference between genders
[16]. Of the 1 362 participants, we could analyse the
HOMA index in 1 177 individuals. The HOMA index of
the study participants in each age group is shown in table 1.
Crude prevalence of laboratory evidence for unknown
PreD and T2DM (table 2)
Of 450 individuals with a normal HbA1c (33.0%, 95% CI
30.6–35.6), 370 participants (82.2%, 95% CI 78.4–85.5)
had a normal FPG, 78 participants (17.3%, 95% CI
14.1–21.1) had a prediabetic FPG, and 2 participants
(0.4%, 95% CI 0.1–1.6) had a diabetic status according to
the FPG cutoffs.
Of the 806 participants with a prediabetic HbA1c (59.2%,
95% CI 56.5– 61.8), 549 subjects (68.1%, 95% CI
Figure 2
Prevalence of unknown prediabetes (PreD) and type 2 diabetes
mellitus (T2DM) by age group. The prevalence of impaired fasting
glucose (suppositious PreD) and T2DM continued to increase with
age older than 60 years, and there is a curve exhibiting saturation
characteristics from age 80 years onwards.
Figure 3
HOMA index according to a diagnosis of T2DM, as obtained from
measurement of FPG and HbA1c. Gluc + indicates a FPG ≥7 mmol/
l, whereas HbA1c + indicates an HbA1c ≥6.5%. Individuals meeting
one or two diagnostic criteria had significantly higher HOMA indices
than individuals without indication of T2DM.
FPG = fasting plasma glucose; Gluc = glucose; HbA1c = glycated
haemoglobin; HOMA = homeostasis model assessment; T2DM =
type 2 diabetes mellitus
64.8–71.2) had a normal FPG, 251 subjects (31.1%, 95%
CI 28.0–34.4) displayed a prediabetic FPG, and 6 subjects
(0.7%, 95% CI 0.35–1.6) had a diabetic status according to
the FPG.
The crude prevalence of subjects with unknown T2DM
was 8.4% (95% CI 7.0–9.9; n = 114), as measured with
both tests. Of the 106 participants with diabetic HbA1c
(7.8%, 95% CI 6.5–9.3), 23 subjects (21.70%, 95% CI
14.9–30.5) had a normal FPG, 51 subjects (48.1%, 95% CI
38.8–57.5) displayed a prediabetic FPG, and 32 subjects
(30.2%, 95% CI 22.3–39.5) had a diabetic status according
to the FPG. Screening with HbA1c alone left 8 undetected
(7.1%, 95% CI–3.6, 13.2), and screening with FPG alone
left 74 undetected (64.9%, 95% CI 55.8–73.1). The preval-
ence of undetected T2DM, when using only HbA1c or gluc-
ose as a screening parameter, was statistically higher in in
males (70/613; 11.4%, 95% CI 9.1–14.2) than in females
(44/749; 5.7%, 95% CI 4.4–7.8) (p = 0.01).
The crude prevalence of individuals who were unaware of
having PreD, which was detected with a combination of the
FPG and HbA1c, was 64.5% (95% CI 61.8–66.9; n = 880).
Regarding the 878 participants without T2DM displaying
PreD diagnosed with either FPG or HbA1c, screening with
FPG alone left 549 undetected (62.5%, 95% CI 59.3–65.7)
and screening with HbA1c alone left 78 undetected (8.9%,
95% CI 7.2–10.9). The proportion of PreD undetected by
either impaired fasting glucose levels or prediabetic HbA1c
was significantly (p <0.001) higher in women (392/749;
52.3%, 95% CI 48.8–55.9) than in men (235/613; 38.3%,
95% CI 34.6–42.2).
Together, when looking at agreement between fasting
plasma glucose and HbA1c to diagnose PreD and T2DM,
the weighted Cohen’s kappa was 0.19, indicating poor
agreement between the two methods in diagnosing disor-
ders of glucose metabolism in healthy seniors. With pro-
gressing age, the prevalence of PreD and T2DM increased,
and the curve exhibited saturation characteristics after 80
years (fig. 2).
In the analysed cohort, 87 individuals (33 women, 54 men)
declared being smokers. Of these, 12 showed evidence
of T2DM (5 women, 15.2%, 95% CI 6.8–31.1; 7 men,
13.0%, 95% CI 6.5–24.5), whereas 51 showed evidence
of PreD (16 women, 48.5%, 95% CI 32.4–64.9; 35 men,
64.8%, 95% CI 51.4–76.2). The respective prevalences in
the 1 275 non-smokers (716 women, 559 men) were: 102
(39 women, 5.4%, 95% CI 4.0–7.4; 63 men, 11.3%, 95%
CI 8.9–14.2) with T2DM, and 880 (515 women, 58.5%,
95% CI 55.2–61.7; 375 men, 42.6%, 95% CI 39.4–45.9)
with PreD. The prevalence of PreD (p = 0.03) and T2DM
(p = 0.049) was significantly higher in female smokers,
whereas no such differences in prevalence could be ob-
served among males.
There are two ranges for decision limits, a wider one (FPG:
5.6–6.9 mmol/l, HbA1c 5.7–6.4%) set by the WHO and a
narrower one (FPG 6.1–6.9 mmol/l, HbA1c 6.0–6.4%) sug-
gested by Heianza et al. [17]. With a recent publication
from the Japanese health authorities that clearly establishes
that narrow decision limits allow for predicting progression
to T2DM with a high degree of certainty, we compared our
data, which were classified into both the wider ADA and
more narrow Japanese intervals. The results are shown in
Original article Swiss Med Wkly. 2015;145:w14209
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table 3. When the criteria set by Heianza et al. were applied
to the group investigated, the number of individuals with
PreD dropped substantially compared with the number of
individuals diagnosed according to ADA criteria and Hei-
anzas’ recommendation [17].
Our study population had mean HOMA indices for the dif-
ferent age groups of between 2.12 and 2.59 (table 1). Be-
cause evidence of an increase in the HOMA-IR in over-
weight subjects is accruing, we also compared this index
with the BMI, but they were not significantly associated (p
>0.05). It should be noted that 3.12–8.78% of individuals
in all age groups had a HOMA index >5.0. When looking at
HOMA-Indices of individuals without any (neither diabet-
ic FPG or HbA1c), with one (either FPG or HbA1c) or with
two (FPG and HbA1c) criteria diagnostic for T2DM, signi-
ficant differences could be seen (p <0.001; fig. 3). Post-hoc
analysis revealed that individuals with nondiabetic FPG
and diabetic FPG as well as individuals with diabetic FPG
and nondiabetic HbA1c had significantly higher HOMAin-
dices than individuals without indication of T2DM. Indi-
viduals with diabetic FPG (irrespective of HbA1c status)
had a significantly higher HOMA index than individuals
with diabetic HbA1c and nondiabetic FPG (<0.05). There
was no difference between individuals with diabetic FPG
having either diabetic or nondiabetic HbA1c.
Discussion
With scarce prevalence data on PreD in Switzerland, we
realise that our study is the first to evaluate participants
aged 60+ years old, who were recruited among the healthy
elderly as part of screening for laboratory evidence point-
ing to PreD and T2DM [18]. In Europe there are approx-
imately 56 × 106 overt T2DM patients, with an estimated
46.0% of cases that are undiagnosed [19]. The so far es-
timated 4.0 to 7.0% of the Swiss population suffering from
T2DM [1] is reflected in our study, with 74 of 1 467 sub-
jects declaring manifest T2DM (5.0% = excluded parti-
cipants). The prevalence of cases, unknown prior to study
entry, with laboratory-associated T2DM was estimated to
be as high as 8.4% (n = 114); for PreD, it was as high as
64.5% (n = 878).
The ADA’s international expert committee recently recom-
mended the adoption of the HbA1c assay for diagnosing
T2DM at a cut-off point of 6.5% and PreD at a cut-off of
5.7–6.4% [20]. According to the ADA, the HbA1c more
closely reflects the long-term (hyper)glycaemic exposure
than the current diagnostic tests that are based on point-in-
time measures of the fasting and post-load blood glucose
[13].
In the USA population, few subjects with PreD are detected
in general healthcare (4.8%); the majority of the cases re-
main undiagnosed and untreated [21]. In 2005 and 2006,
only approximately 7.0% of people in the USA with PreD
were aware of their condition, regardless of their educa-
tional level, income level, or healthcare access status [7,
22]. An impending hyperglycaemic state is an occult health
condition that places patients at a high risk of developing
T2DM (5.0–10.0% of people per year) [23]. The diagnostic
precision for impending T2DM is substantially improved
by use of the combination of FPG and HbA1c for screening.
On meta-analysis, many reports on the FPG and HbA1c
screening tests struggle to distinguish between laboratory
and clinically based diagnosis, and good clinical practice
calls for second, confirmatory test efforts, including an
OGTT. Interpretation of the results reported here should re-
frain from overdiagnosis, but our findings cannot be dis-
counted as false positive results
(www.choosingwisely.org).
Laboratory T2DM went undetected less frequently in wo-
men than in men, as assessed with the HbA1c and FPG.
This may reflect the current Swiss national data showing
inequality in the prevalence between men and women, with
a prevalence of 13.9–18.2% in men ≥65 years compared
with 8.4–8.8% for women ≥65 years [24], in agreement
with a 25–41-year age group recently addressed [2]; pre-
dominance of smokers in men at least is in line with previ-
ous evidence for nicotine-related impaired glucose regula-
tion [25] without, however, reaching statistical power since
only 87 participants declared tobacco use.
If evaluated with the HbA1c, women more frequently
presented with PreD, whereas screening with the FPG
levels had the opposite result. Again, the fact that more
men are detected with impaired glucose regulation when
tested with the FPG reflects the high prevalence of T2DM
in the Swiss male population [1]. In this regard, the gender-
neutral BMI of our population did not play a relevant role.
One study previously published also reported a gender dif-
ference in the FPG test, including the observation of a
higher prevalence among men [26]. The diagnostic power
of the HbA1c test over the FPG test is the improvement
in identifying T2DM, making it possible to take care of
high-risk patients, namely subjects who were unaware of
their T2DM status, in a timely manner; therefore both tests
should be utilised in the search for unknown prediabetic
and diabetic glycaemic states. On the other hand, our res-
Table 3: Prevalence of impaired glucose metabolism, PreD and T2DM according to the ADA criteria and based on a combination of narrowing cut-offs as published by
Heianza et al. [17].
ADA criteria ADA criteria Heianza et al. Heianza et al.
HbA1c
5.7–6.4%
FPG
5.6–6.9 mmol/l
HbA1c
6.0–6.4%
FPG
6.1–6.9 mmol/l
PreD, n, %
Men, n (%)
Women, n (%)
806 (59.2)
332 (41.2)
474 (58.8)
380 (27.9)
224 (58.9)
156 (41.1)
355 (44.0)
150 (42.2)
205 (57.8)
118 (30.1)
75 (63.6)
43 (36.4)
Combination of HbA1c 5.7–6.4% and FPG 5.6–6.9 mmol/l Combination of HbA1c 6.0–6.4% and FPG 6.1–6.9 mmol/l
PreD, n, %
Men, n (%)
Women, n (%)
251 (18.4)
142 (56.6)
109 (43.4)
54 (21.5)
31 (57.41)
23 (42.59)
ADA = American Diabetes Association; FPG = fasting plasma glucose; HbA1c = glycated haemoglobin; PreD = prediabetes;
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ults are in line with other studies that have concluded that
the use of the HbA1c criteria alone leads to a lower PreD
prevalence [10, 27]. Unsolicited screening uncovering im-
paired glucose regulation could be used to motivate those
ready to adjust their lifestyle to prevent diabetes, the more
so as such health policy brings harm reduction, for both the
patients and health costs (Memorandum of Understanding,
www.news.admin.ch 2015).
Even though differences in dietary composition among
races do exist, data from our regional study cohort may
support the conclusion of a Japanese study of over 6 000
participants, in which a combination of both narrowing RIs
for the HbA1C to 6.0–6.4% and FPGs to 6.1–6.9 mmol/l
produced a cumulative risk ratio close to 100% in predict-
ing progression to T2DM [28]. At least, genetic susceptib-
ility loci for T2DM should not differ much across popula-
tions of diverse ancestry [29].
Life expectancy, which is increasing at a rate of ~2 months
per year in Switzerland, has now reached 84.7 years for
women and 80.5 years for men. Accordingly, the increase
in laboratory-based and clinically manifest T2DM, in ad-
dition to being related to the more frequent opportunistic
screening of a steadily growing healthy aged population,
is due to the increasing life expectancy. From a patho-
physiological point of view, the age-related decline in pan-
creatic islet function and the increase of insulin resistance
has been confirmed in several studies [30–32]. Therefore,
we postulate that the reason for the phenomena in our older
study population may be the higher mortality rate in in-
dividuals with unknown subdiabetic and diabetic hyper-
glycaemia and associated risks.
A graded dose-response relationship between exercise and
the improvement in insulin sensitivity has been proposed
[33]. This could explain why endurance training in older
people with PreD delays the development of overt T2DM
[34]. Several studies emphasize the prevention of T2DM
through changes in lifestyle among subjects with impend-
ing diabetes [35]. However, regrettably, this does not result
in reductions in all-cause cardiovascular mortality [36], the
more so as the very old (≥85 years) when frail, will be un-
able to change lifestyle.
Without taking adequate measures, a gradual progression
of the diabetic state will lead to micro- and macrovascular
complications; older adults aged ≥75 years are more at risk
than those aged 65–75 years [37]. People whose test results
indicate they have impending hyperglycaemia should have
their FPG checked again in 6-month to 1-year intervals
[7]. Basic research approaches likely lead to improved dia-
gnostic precision of impaired glycaemia control [38, 39].
Strengths and limitations of the study
This is the first time that healthy Swiss senior citizens have
been strictly screened for impaired glycaemic control, sug-
gestive of PreD and constituting a risk for later develop-
ment of T2DM if not already present from a laboratory
perspective. Our study underlines the need for the early
identification of impaired glycaemic control and diabetic
hyperglycaemia in older healthy subjects to reduce the in-
cidence of potentially modifiable risks early on (e.g., cardi-
ovascular, overweight, hypertension) aggravating disturbed
metabolic status.
The study is cross-sectional, and we cannot show data
about progression to clinically relevant conditions in our
study population. Furthermore, we analysed only subject-
ively healthy older people, limiting the external validation
to a general population. Indeed, the prevalence of PreD in
the general population may be even higher. The single FPG
test would have been strengthened with the use of a second
examination or glycaemic profile; an OGTT was not con-
sidered for ethical concerns. Future studies should define
whether early diagnosis of patients with PreD using the
new ADA recommendations is cost effective and translates
into improved outcomes of seemingly healthy individuals.
Conclusions
PreD (64.5%) and T2DM (8.4%), based on laboratory
screening, occur frequently among subjectively healthy
Swiss senior citizens, according to the current ADA criter-
ia. This calls for increased vigilance in identifying occult
occurrence of metabolic disturbances in older people. The
introduction of HbA1c as a screening parameter has in-
creased the prevalence of T2DM by a factor of 1.6 com-
pared with screening with the FPG alone. The high rate of
abnormal glyacemic plasma levels, together with sedentary
lifestyles in a senior population, make it likely that diabetes
will continue to be a major problem in Switzerland if we
do not fight against this trend. We need to identify appar-
ently healthy subjects with clinically occult impaired gluc-
ose regulation and/or diabetic hyperglycaemia in a timely
manner to adopt immediate preventive lifestyle modifica-
tions and/or therapeutic interventions.
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Figures (large format)
Figure 1
Study flow diagram.
In addition to the exclusions for known diabetes mellitus, we had to exclude subjects in whom the relevant laboratory tests were not available. *
Four participants fulfilled both exclusion criteria.
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Figure 2
Prevalence of unknown prediabetes (PreD) and type 2 diabetes mellitus (T2DM) by age group. The prevalence of impaired fasting glucose
(suppositious PreD) and T2DM continued to increase with age older than 60 years, and there is a curve exhibiting saturation characteristics
from age 80 years onwards.
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Figure 3
HOMA index according to a diagnosis of T2DM, as obtained from measurement of FPG and HbA1c. Gluc + indicates a FPG ≥7 mmol/l, whereas
HbA1c + indicates an HbA1c ≥6.5%. Individuals meeting one or two diagnostic criteria had significantly higher HOMA indices than individuals
without indication of T2DM.
FPG = fasting plasma glucose; Gluc = glucose; HbA1c = glycated haemoglobin; HOMA = homeostasis model assessment; T2DM = type 2
diabetes mellitus
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